UNSPSC 51334207: Quetiapine fumarate

This classification denotes a serotonin antagonist and antipsychotic agent with the molecular formula 2C21H25N3O2S.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2S3PL1B6UJ, chemically known as 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)ethanol fumarate ( but more generally known as quetiapine fumarate, which bears US NIH Compound Identifier 5002. European Medicines Agency schedules Quetiapine fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15074MIG.

UNSPSC 51334207 Quetiapine fumarate is a Commodity code that nominally designates a single pharmaceutical product, but recent state and local procurement activity under this code shows minimal relevant solicitation. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, a request for information on direct-to-manufacturer pharmacy programs, and a multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products—none of which center on quetiapine fumarate procurement. The mismatch suggests either miscoding in the state and local procurement management systems or that actual quetiapine fumarate buying occurs under higher-tier pharmaceutical family or class codes rather than this specific commodity designation.

When state and local buyers do solicit pharmaceutical products at the commodity level, the issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). Geographic activity appears concentrated in the Southeast (Florida) and Southwest (Texas), with participation from multistate groups spanning the Upper Midwest and Pacific Northwest. A representative recent opportunity is Seminole County's IFB60459723LAS (due July 26, 2023, via competitive bidding), which solicited naloxone and safe drug deactivation systems with quarterly deliveries and fixed-fee pricing. Another is MMCAP's RFP S1070000015802 (due March 26, 2026), a two-year multistate agreement for generic pharmaceuticals and OTC products distributed through three authorized national wholesalers, with price competitiveness weighted at 75 percent of the evaluation and participation open to manufacturers meeting cGMP and Drug Supply Chain Security Act compliance. The code shows little activity directly tied to quetiapine fumarate itself; a firm pursuing state and local pharma sales should track higher-tier pharmaceutical family codes (UNSPSC 51330000 or equivalents) where generic and brand-name drug procurement concentrates.